Quick Answer
SANGAMO THERAPEUTICS, INC reported Total Revenue of $39.55 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -31.6% in Total Revenue from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2009 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $6.87 million | Q1 2014: $8.12 million | Q2 2014: $10.39 million | Q3 2014: $12.42 million | Q4 2014: $14.95 million | Q1 2015: $13.49 million | Q2 2015: $8.36 million | Q3 2015: $8.57 million | Q4 2015: $9.12 million | Q1 2016: $3.94 million | Q2 2016: $3.70 million | Q3 2016: $2.82 million | Q4 2016: $8.92 million | Q1 2017: $3.43 million | Q1 2017: $3.43 million | Q2 2017: $8.25 million | Q2 2017: $8.25 million | Q3 2017: $11.81 million | Q3 2017: $11.81 million | Q4 2017: $13.08 million | Q4 2017: $13.08 million | Q1 2018: $12.64 million | Q1 2018: $12.64 million | Q2 2018: $21.42 million | Q3 2018: $23.56 million | Q4 2018: $26.84 million | Q1 2019: $8.07 million | Q2 2019: $17.55 million | Q3 2019: $21.96 million | Q4 2019: $54.85 million | Q1 2020: $13.08 million | Q2 2020: $21.55 million | Q3 2020: $57.76 million | Q4 2020: $25.80 million | Q1 2021: $26.28 million | Q2 2021: $27.87 million | Q3 2021: $28.56 million | Q1 2022: $28.23 million | Q2 2022: $29.38 million | Q3 2022: $26.46 million | Q1 2023: $157.96 million | Q2 2023: $6.84 million | Q3 2023: $9.40 million | Q1 2024: $481.0 thousand | Q2 2024: $356.0 thousand | Q3 2024: $49.41 million | Q1 2025: $6.44 million | Q2 2025: $18.31 million | Q3 2025: $581.0 thousand.
- Over the full 19 years of available data (2009 to 2025), SANGAMO THERAPEUTICS, INC's Total Revenue has grown by 78.3%.
- Historical annual values: Fiscal year 2025: $39.55 million | Fiscal year 2024: $57.80 million | Fiscal year 2023: $176.23 million | Fiscal year 2022: $111.30 million | Fiscal year 2021: $110.70 million | Fiscal year 2020: $118.19 million | Fiscal year 2019: $102.43 million | Fiscal year 2018: $84.45 million | Fiscal year 2017: $36.57 million | Fiscal year 2017: $36.57 million | Fiscal year 2016: $19.39 million | Fiscal year 2016: $19.39 million | Fiscal year 2015: $39.54 million | Fiscal year 2014: $45.87 million | Fiscal year 2013: $24.13 million | Fiscal year 2012: $21.66 million | Fiscal year 2011: $10.32 million | Fiscal year 2010: $20.81 million | Fiscal year 2009: $22.19 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: